RegulationPriority Review (United States), Accelerated Approval (United States), Priority Review (China), Breakthrough Therapy (China), Commissioner's National Priority Voucher (United States), Conditional marketing approval (Canada)

Structure/Sequence

Sequence Code 50953

Source: *****

650

Clinical Trials associated with Semaglutide (Novo Nordisk)

NCT07586150

/ Not yet recruitingNot ApplicableIIT

Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive Technologies

This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.

Start Date01 Oct 2028

Sponsor / Collaborator

Ludwig-Maximilians-Universität München

NCT07430332

/ Not yet recruitingPhase 2IIT

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Start Date01 Sep 2027

Sponsor / Collaborator

Children's Hospital & Medical Center

NCT07754045

/ Not yet recruitingPhase 2

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity

This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m^2, between the ages of 60 and 85 years that have mild functional impairment.

Start Date15 Feb 2027

Sponsor / Collaborator

Lumos Pharma, Inc.

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

396

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Sep 2026·RESPIRATORY MEDICINE

GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis

Article

Author: Altschul, David J ; Sharma, Sunil ; Praveen, Niharika ; Essibayi, Muhammed Amir ; Latifi, Shahrzad ; Lakhani, Dhairya A ; Colasurdo, Marco ; Dmytriw, Adam A ; Azzam, Ahmed Y ; Bathla, Girish ; Rai, Pranjal ; Chen, Huanwen Alvin ; Malhotra, Ajay ; Yedavalli, Vivek S ; Salim, Hamza A ; Gandhi, Dheeraj

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1As) confer cerebrovascular benefits in diabetes and obesity, but their long-term effects in obstructive sleep apnea (OSA), which is frequently associated with obesity and linked to poor cerebrovascular outcomes, remain unclear.

METHODS:

We conducted a retrospective cohort study using the TriNetX US Collaborative Network between January 1st 2016 to December 31st 2025. Adults with OSA were identified; exposure was initiation of a GLP-1A within 6 months before up to 1 month after OSA diagnosis. Propensity score matching was performed 1:1. Outcomes were assessed at 1, 3, and 5 years and included ischemic stroke, intracranial hemorrhage, emergency department visits, inpatient hospitalizations, and all-cause mortality. Kaplan-Meier analyses and Cox proportional hazards models were used. CPAP-restricted and tirzepatide-specific subgroup analyses were also performed.

RESULTS:

After matching, 438,844 patients were included in each cohort. Across 1-, 3-, and 5-year follow-up, GLP-1A exposure was associated with lower hazards of ischemic stroke (HRs, 0.75, 0.83, and 0.87), intracranial hemorrhage (HRs, 0.44, 0.56, and 0.61), emergency department visits (HRs, 0.77, 0.86, and 0.87), inpatient hospitalizations (HRs, 0.59, 0.67, and 0.69), and all-cause mortality (HRs, 0.38, 0.49, and 0.54; all p < 0.001). Associations were directionally consistent in CPAP-restricted and tirzepatide-specific subgroup analyses.

CONCLUSIONS:

In this large real-world cohort of patients with OSA, GLP-1A exposure was associated with lower hazards of cerebrovascular events, healthcare utilization, and all-cause mortality across 1-, 3-, and 5-year follow-up. These findings are hypothesis-generating and require validation in prospective studies evaluating incretin-based therapies as potential adjuncts to standard OSA management.

01 Sep 2026·JOURNAL OF CLINICAL NEUROSCIENCE

GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis

Article

Author: Lakhani, Dhairya A ; Salim, Hamza A ; Praveen, Niharika ; Latifi, Shahrzad ; Essibayi, Muhammed Amir ; Aggarwal, Eishvauk ; Altschul, David J ; Kakadiya, Jay ; Colasurdo, Marco ; Dmytriw, Adam A ; Dhaduk, Vidhi ; Gandhi, Dheeraj ; Azzam, Ahmed Y ; Bathla, Girish ; Rai, Pranjal ; Chen, Huanwen Alvin ; Malhotra, Ajay ; Yedavalli, Vivek S

BACKGROUND:

Glucagon-like peptide-1 receptor agonists (GLP-1As) have demonstrated cardiovascular and cerebrovascular benefits in high-risk populations, but their impact in patients with acute ischemic stroke (AIS) requiring endovascular thrombectomy (EVT) remains uncertain.

METHODS:

We performed a retrospective cohort analysis using the TriNetX Network, identifying adults (≥18 years) with AIS treated with EVT from January 1, 2016 through December 31, 2025. Patients with GLP-1A exposure within three months prior to EVT constituted the exposure cohort; those without served as comparators. This pre-index window was specified to eliminate immortal time bias, with follow-up beginning on the EVT date for both cohorts. Three-year outcomes included all-cause mortality and inpatient hospitalizations. One-to-one propensity score matching was applied using demographic, comorbidity, medication, and metabolic variables including individual National Institute of Health Stroke Scale scores, Hemoglobin A1c, and body mass index.

RESULTS:

Among 286 GLP-1A-exposed and 19,263 unexposed EVT-treated patients, 261 matched pairs were analyzed. GLP-1A use was associated with lower all-cause mortality (11.5% vs 29.9%; HR 0.334, 95% CI 0.219-0.508) and fewer inpatient hospitalizations (39.8% vs 54.8%; HR 0.514, 95% CI 0.398-0.663), both p < 0.001.

CONCLUSIONS:

Among EVT-treated AIS patients, GLP-1A exposure within three months prior to EVT was associated with improved survival and reduced inpatient hospitalizations.

01 Aug 2026·DIABETES OBESITY & METABOLISM

Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III , Active‐Controlled Study

Article

Author: Shah, Akash Nitinbhai ; Dasari, Mani Deepathi ; Kurmi, Prakash Harishchandra ; Patil, Dipak ; Patel, Nitesh Chandubhai ; Deshpande, Shrikant Vishnu ; Das, Bharat ; Pathak, Niranjan Pandurang ; Chennappa, Madhusudhan ; Sonawane, Dipesh ; Shende, Prakash Sadashiv ; Ambika Gopalakrishnan, Unnikrishnan ; Ghadge, Pravin ; Patil, Sandesh Sahebarao ; Pandit, Sucheta ; Singh, Manish Kumar ; Shukla, Jitendra ; Shah, Shalin Jagdeep ; Jangid, Sanjay Kumar ; Maheshwari, Sanjiv ; Virani, Mehul Kalubhai ; Bhandari, Shweta ; Mehta, Suyog ; Giri, Richa ; Gowda, Ambanna ; Supe, Pravin Dinkar ; M. Chowdaiah, Rekha ; Kumbhar, Avinash Narayan ; Sharma, Prabhat Kumar ; Sahoo, Banshidhar ; Joshi, Ameya Sudhakar ; Chandrappa, Ambrish ; Ghanekar, Gayatri Amit ; Bari, Aditya Srirang

ABSTRACT:

Aim:

To evaluate the efficacy, safety and immunogenicity of semaglutide injection (synthetic) (Test group) compared with the Reference semaglutide injection [Ozempic, (Reference group)] in Indian patients with Type 2 diabetes mellitus (T2DM).

Materials and Methods:

This Phase III, randomised, open‐label, multi‐centre, parallel‐group, active‐controlled non‐inferiority study was conducted across 35 centres in India. Adults aged 18–65 years with T2DM and baseline glycated haemoglobin (HbA1c) ≥ 7.0% to ≤ 10.5% despite stable metformin therapy and diet & exercise control were randomised (1:1) to receive subcutaneous injections of Test semaglutide or Reference semaglutide once weekly for 24 weeks, using an identical dose‐escalation regimen (from 0.25 to 2.0 mg per week). The primary endpoint was change in HbA1c from baseline to Week 24. Secondary endpoints included changes in fasting and post‐prandial blood glucose, bodyweight and HbA1c < 7.0% achievers, safety and immunogenicity.

Results:

A total of 314 patients were randomised, and 290 patients completed the study. At Week 24, both treatments produced significant and comparable reductions in HbA1c (Test: −2.04%, Reference: −1.95%; p < 0.0001 within groups). The least‐squares mean difference (Test‐Reference) was −0.09% (95% CI: −0.26 to 0.09), meeting the pre‐specified non‐inferiority criterion. Improvements in fasting and post‐prandial blood glucose, patients achieving HbA1c < 7.0% and bodyweight were similar between the two groups. The most common treatment‐emergent adverse events were predominantly mild‐to‐moderate gastrointestinal events (Test vs. Reference: 43.3% vs. 46.5%). No anti‐drug or neutralising antibodies were detected.

Conclusions:

The Test synthetic semaglutide injection demonstrated non‐inferior glycaemic efficacy, comparable safety in comparison to Reference semaglutide, supporting its use as an effective therapeutic option for patients with T2DM. Prospectively registered on the Clinical Trials Registry—India, CTRI/2025/02/080592 [Registered on: 14/02/2025], URL: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=MTIwODUw&Enc=&userName= .

3,279

News (Medical) associated with Semaglutide (Novo Nordisk)

15 Aug 2026

·www.sciencedaily.com

Scientists solve the mystery of a brain “switch” that can trigger weight loss in opposite ways

Scientists have uncovered why two seemingly opposite ways of targeting the same brain receptor can both promote weight loss. In mice, activating the GIP receptor in the brainstem reduced appetite, while blocking it in the hypothalamus removed a kind of “brake” on fullness signals. The discovery helps explain why very different obesity drugs can achieve similar results and suggests that carefully combining GIP-targeting treatments with GLP-1 drugs like those related to Wegovy and Ozempic could produce stronger effects.Cambridge researchers have uncovered why both activating and blocking the same brain receptor can promote weight loss. The findings may help scientists develop obesity treatments that are more effective and potentially work better in combination. The mouse study, published in Nature Metabolism, found that the outcome depends on which part of the brain is targeted. Activating the receptor in the brainstem reduced appetite, while blocking the same receptor in the hypothalamus produced a similar weight loss effect through a different mechanism. More than a billion people around the world are living with obesity, a condition that raises the risk of diseases including type 2 diabetes, cardiovascular disease and cancer. Losing weight can reduce some of these risks, but achieving substantial weight loss through diet and exercise alone can be difficult. How Modern Weight Loss Drugs Target the Brain A new generation of weight loss medications has emerged in recent years that act on specific receptors involved in appetite. By influencing these receptors, the drugs can reduce food intake, promote weight loss, and help regulate blood sugar. Several widely used medications, including Wegovy and Ozempic, activate a protein receptor called the glucagon-like peptide 1 receptor (GLP-1R). Other obesity treatments act on both GLP-1R and another receptor known as the glucose-dependent insulinotropic polypeptide receptor (GIPR). This second target has presented scientists with an unusual puzzle. Some medications, including Mounjaro and Zepbound, activate GIPR. Others, such as MariTide, block it. Despite producing opposite effects on the same receptor, both approaches can help promote weight loss. Researchers at the Institute of Metabolic Science, University of Cambridge, set out to understand why. Their experiments in mice revealed that the two types of GIPR drugs work through different regions of the brain. The researchers also found that these approaches can increase weight loss when paired with certain GLP-1-based weight loss medicines. Tracking GIPR Activity in Different Brain Regions To identify the brain regions responsible for these effects, the team used genetically engineered mice in which GIPR had been selectively removed from specific areas. One group lacked GIPR in the brainstem, the region at the base of the brain just above the spinal cord that is involved in appetite and nausea. Another group lacked the receptor in the hypothalamus, an important brain region involved in regulating hunger and body weight. A third group consisted of normal, unmodified mice that served as controls. The scientists treated the animals with different combinations of a GIPR agonist (which activates the receptor), a GIPR antagonist (which blocks the receptor) and a GLP-1 drug. They then monitored food consumption, body weight, fat mass, blood sugar control and brain activity. Comparing the different groups allowed the team to pinpoint where each treatment was acting. The results showed that GIPR agonists primarily work through the brainstem. Activating GIPR in this region reduced appetite and led to lower body weight. Blocking a Brain Brake on Fullness GIPR antagonists followed a different route. Instead of acting primarily through the brainstem, the researchers found that blocking GIPR promoted weight loss through the hypothalamus. In this region, GIPR appears to function as a kind of 'brake' that limits how strongly the brainstem responds to signals indicating that the body is full. Blocking the receptor effectively releases that 'brake', allowing fullness signals to have a stronger effect. The researchers also found evidence that blocking GIPR could enhance the effects of emerging medicines that target the amylin receptor. This suggests that GIPR antagonists might eventually be useful for strengthening several different classes of obesity treatments. Clues to More Powerful Obesity Drug Combinations The results help explain why treatments such as MariTide can be effective. MariTide, currently in phase 3 clinical trials, combines GIPR antagonism with GLP-1 receptor agonism. Understanding how these separate pathways interact could also help researchers design more effective combinations of obesity medicines in the future. Dr. Jo Lewis, the study's first author from the Institute of Metabolic Science at the University of Cambridge, said: "Understanding which brain circuits respond to these medications - and how they do so - could help us design better drugs that produce more weight loss with fewer side effects, and which might work in combination with other obesity medicines to even greater effect. "Our work also strengthens the idea that the brain is central to obesity treatment. Obesity drugs are not acting simply on the gut or pancreas. Instead, they have important effects on specific, identifiable brain circuits that regulate appetite and food intake." The research was funded by the Medical Research Council and Wellcome.

Phase 3Clinical Result

15 Aug 2026

·healthcare-digital.com

This Week’s Top 5: Eli Lilly's GLP-1, Novo Nordisk and P&G

Eli Lilly has multiple prominent medications for weight loss and diabetes. Credit: Eli Lilly This week's top stories include Eli Lilly's European first pill, BMS' Texan manufacturing, Novo Nordisk's GLP-1, AWS AI partnership & P&G's wellness move 1. First in Europe: UK Approves Eli Lilly’s Weight Loss Pill The UK has become the first country in Europe to approve orforglipron, an oral GLP-1 medicine developed by Eli Lilly for weight management and type 2 diabetes. The Medicines and Healthcare products Regulatory Agency (MHRA) authorised the treatment on 10 August 2026 following an assessment of its safety, quality and effectiveness. The once-daily tablet offers an alternative to injectable GLP-1 medicines , with no food or water restrictions when taken. Marketed as Foundayo, orforglipron is authorised for weight loss and weight maintenance in adults with a BMI of 30 or above, or those with a BMI between 27 and 30 alongside at least one weight-related comorbidity. 2. Bristol Myers Squibb’s US$2.3bn Texas Manufacturing Campus BMS' Houston, Texas, US, facility will span 600,000 square foot. Credit: Bristol Myers Squibb Bristol Myers Squibb (BMS) is deepening its commitment to US biopharmaceutical manufacturing with a US$2.3bn "multi-modal manufacturing campus" in Houston, Texas. The announcement marks a milestone step in its US$40bn plan to invest in US research and development, technology and domestic manufacturing over five years. "This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation,” says Christopher Boerner, Board Chair and CEO of BMS. “As part of our US$40bn commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life." 3. Novo Nordisk Appoints Omnicom For GLP-1 Medication Awareness Novo Nordisk has concentrated its marketing resources on GLP-1 medications Novo Nordisk has appointed Omnicom as agency of record for its US media account. The pharmaceutical manufacturer ended its partnership with WPP, which had held the media buying contract since 2020. The change comes as Novo Nordisk scales its consumer engagement for GLP-1 treatments Ozempic and Wegovy. Liz Skrbkova, Head of US Media and Stakeholder Relations for Novo Nordisk , shared with Fierce Pharma Marketing that the company looks forward "to working with the Omnicom team as we continue to scale consumer-focused strategies and connect with patients through emerging channels and technologies, helping bring even greater awareness of our medicines to people living with chronic conditions such as obesity and diabetes". 4. Novo Nordisk and AWS Partner on “AI Co-Innovation Hub” Novo Nordisk is building capabilities across the computing and AI spectrum. Credit: Novo Nordisk A strategic partnership between Novo Nordisk and Amazon Web Services (AWS) aims to expedite drug discovery and modernise Novo Nordisk’s operations through agentic AI and cloud technologies. Central to the partnership is a “co-innovation hub” in London, where engineers, AI specialists, R&D teams and scientists from both firms will leverage AWS AI technologies alongside Novo Nordisk’s data and insights to shorten the timeline from initial drug target to first human dose. “Partnering with AWS is about making AI a driver of innovation across Novo Nordisk,” says Mike Doustdar, President and CEO of Novo Nordisk. “By combining our scientific expertise with AWS’ tools and purpose-built services for the life sciences industry, while also creating a dedicated co-innovation hub within our existing facility in London, we are accelerating discovery and developing responsible AI solutions that will create real progress for people living with serious chronic diseases.” 5. P&G’s Wellness Focus Grows Following US$3.8bn Thorne Deal The global vitamins, minerals and supplements (VMS) market is estimated to be worth more than US$160bn. Credit: Leo Hoho / Unsplash Global consumer goods giant Procter & Gamble (P&G) is expanding its Health Care portfolio following its US$3.8bn acquisition of Thorne, as the company looks to tap into rising consumer interest in self-care, preventive health and personalised wellness. P&G’s Health Care portfolio has evolved from a traditional consumer healthcare business centred on oral care and OTC medicines into a broader health and wellness platform. The global consumer health market exceeds an estimated US$375bn in retail sales, with P&G well-positioned to maintain its strong presence in the sector. Household brands already within its Health Care portfolio include Vicks, Crest, Oral-B, Metamucil, Pepto-Bismol, Fixodent, and Neurobion, alongside supplement brands Align Probiotic and New Chapter. Writing on LinkedIn, Paul Gama, CEO of P&G Health Care, says, “This is…an amazing brand with a wonderful health practitioner heritage. It's science-backed, quality-driven. I am really looking forward to working with this [the Thorne] team.” Company portals Amazon Web Services (AWS) Bristol Myers Squibb Eli Lilly Novo Nordisk Omnicom Procter & Gamble (P&G) Thorne Executives Chris Boerner Board Chair and Chief Executive Officer Liz Skrbkova Senior Director, US Media & Stakeholder Relations, Issues and Crisis Management Maziar Mike Doustdar President and CEO Paul Gama Chief Executive Officer, P&G Health Care

Drug ApprovalAcquisition

14 Aug 2026

·www.fiercebiotech.com

Skye and Redx form new entity with $125M to advance fibrosis assets

After its last attempt at a merger failed in 2023, Redx Pharma seems to have found a willing partner in Skye Bioscience, which experienced a couple of trial failures in recent years. The public biotech has entered into an agreement to combine with privately held fibrotic disease company Redx in a deal that will net $125 million in financing for a new public company called Fibrx Therapeutics. The deal mirrors the structure of a reverse merger. The combined firm will be led by Redx’s current leadership and focus on advancing Redx’s fibrosis assets, according to a Friday release . Fibrx, which is expected to begin trading on the Nasdaq following the completion of the transaction, will now have runway into 2029 and funds to support its lead asset, RXC008. The drug is a GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn’s disease that is set to begin a phase 2 study. With the added funding, topline data for that study are expected in the second half of 2028. With no approved therapeutic options to address the underlying fibrotic aspects of Crohn’s, patients sometimes must undergo bowel resection surgery or a strictureplasty, in which a section of the bowel is widened to improve digestion. According to a release, preclinical studies have demonstrated RXC008’s potential to reverse fibrosis in the GI tract, and phase 1 studies showed a favorable tolerability and safety profile. The candidate received Fast Track designation from the FDA in January. “We believe this is an exciting opportunity to be a leader in developing a therapeutic option for patients suffering with fibrostenotic Crohn’s disease, considered by many to be one of the largest unmet medical needs in IBD,” said Lisa Anson, Redx’s CEO who will be the CEO of Fibrx. This isn't Redx's first crack at a merger. In 2023, it was set for a reverse merger with Jounce Therapeutics after Jounce conceded its cancer meds were unlikely to advance. But just a few weeks after announcing a planned combination, Concentra Biosciences entered the picture and eventually acquired Jounce. The new deal will give the company a path to public markets and additional financing. Fibrx’s $125 million comes from a variety of new deals, including an agreement Skye signed with new and existing investors, including Abingworth, British Business Bank, NEXTBio Capital and 5AM Ventures, as well as Redx’s existing major shareholder, Redmile, which will total $68 million in private financing. Redx also entered into a subscription agreement for a $36 million Series A financing led by Abingworth that included British Business Bank and Redmile. Additionally, Redmile and Skye agreed to a $22 million equity line that will result in Skye issuing a warrant to Redmile to purchase $5 million worth of stock. San Diego-based Skye has had a few setbacks in recent years. In 2024, it ended its eye disease R&D efforts after its glaucoma drug failed in a phase 2 trial. Last October, phase 2 data showed that its CB1 blocker nimacimab failed to reduce weight much more than the placebo in combination with Novo Nordisk’s GLP-1 drug semaglutide at week 26, sending its stock down 60%. In February, Skye published 52-week data from the extended trial, showing that patients on the combination lost 22.3% of their body weight compared with 19.7% in the semaglutide-only group. According to a release, Skye discontinued that trial, paused nimacimab development activities and sought out strategic alternatives in the second quarter of this year after reviewing the evolving landscape of anti-obesity medicines and potential commercial opportunities for the drug. “We believe this transaction provides our shareholders a compelling opportunity to realize both short- and long-term value creation through Redx’s novel anti-fibrotic therapies, led by their first-in-class pan-ROCK inhibitor, RXC008,” Skye President and CEO Punit Dhillon said in a release. Skye shareholders will also receive 90% of net cash proceeds realized from future monetization of nimacimab and its associated intellectual property, Dhillon added. Beyond its lead asset, Fibrx's pipeline includes a preclinical discoidin domain receptor (DDR) inhibitor program. DDRs are tyrosine kinase collagen receptors that have increased expression in kidney, lung and liver fibrosis. An IND submission for the DDR inhibitor is expected in 2027. Additionally, RXC007 is a selective ROCK2 inhibitor, with potential for use in interstitial lung diseases and other indications such as metabolic dysfunction-associated steatohepatitis (MASH) and cancer-associated fibrosis. The asset, also called zelasudil, has completed a successful signal-searching phase 2 study in idiopathic pulmonary fibrosis (IPF) patients and is a candidate for partnering. Fibrx will be headquartered in Alderley Park, U.K., the current headquarters of Redx, and a majority of the new board will be made up of Redx’s current board. Pre-transaction Skye equity holders are expected to own 5.38% of the combined company, while pre-transaction Redx investors will own 46.17% of the combined company. Investors who participated in the latest round of financing will own the remaining 48.45% of Fibrx.

Phase 2Phase 1Fast TrackClinical ResultAcquisition

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	United Kingdom	Novo Nordisk A/S	01 Apr 2026
Fibrosis, Liver	United States	Novo Nordisk, Inc.	22 Dec 2025
Pulmonary Fibrosis	Canada	Novo Nordisk Canada, Inc.	21 Dec 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	08 Mar 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05132088 (OASIS 2, CTgov)	Phase 3	Obesity	201	Semaglutide (Oral Semaglutide 50 mg)	psjbdwvcnh(jhycgjrcmn) = evqijnflae zrdxqkqndo (ukfwxdugmh, 9.5) View more	-	14 Aug 2026
				Semaglutide (Oral Semaglutide Placebo)	psjbdwvcnh(jhycgjrcmn) = cswhsvsdgn zrdxqkqndo (ukfwxdugmh, 5.0) View more
NCT05035082 (REALYSE, CTgov)	Phase 4	Diabetes Mellitus, Type 2	1,018	semaglutide	aipiumhaph(bnhsnrhrnd) = ijkllmbplc jcvqwfrxfe (udusrrzefa, 1.463) View more	-	10 Aug 2026
NCT05548647 (STABLE Wt Loss, CTgov)	Phase 4	Obesity	120	Placebo (Behavioral Treatment + Placebo (Weeks 0-60))	njpkcomecf(nrelejnsqy) = nztiqmihdl lmiuzlpmcf (aqdzoiufhg, 52.6) View more	-	03 Aug 2026
				semaglutide (Behavioral Treatment + Medication (Weeks 0-60))	njpkcomecf(nrelejnsqy) = fdjiicoxmo lmiuzlpmcf (aqdzoiufhg, 37.2) View more
NCT05813912 (ONWARDS 8, Pubmed \| Diabetes Obes Metab)	Phase 3	Diabetes Mellitus, Type 2	148	once-weekly insulin icodec + once-weekly semaglutide	tpnhalqaqo(meocldcjqu) = ecvqpqiggp zyzgfhgwga (mkuderzgya )	Positive	01 Jul 2026
NCT05537233 (ADJUST-T1D, ADA2026)	Phase 3	Diabetes Mellitus, Type 1	72	Semaglutide	pnnujklaxm(onekcpmfcs) = lixjmcdbiy mtbtmkpnxy (ozdrzfheii )	Positive	20 Jun 2026
				Placebo	pnnujklaxm(onekcpmfcs) = mwqkmqsqch mtbtmkpnxy (ozdrzfheii )
SELECT (ADA2026)	Phase 3	Asthma blood high-sensitivity C-reactive protein [hsCRP]	1,190	Semaglutide 2.4 mg	pxlhzuexpl(phmoefgrtw) = dweiozegfn xqqcoajtqe (dcxjqfnavc ) View more	Positive	20 Jun 2026
				Placebo	pxlhzuexpl(phmoefgrtw) = aythjkwtpg xqqcoajtqe (dcxjqfnavc ) View more
PIONEER PLUS (ADA2026)	Phase 3	Diabetes Mellitus, Type 2	1,012	Oral Semaglutide 50 mg	cynrkklmpf(hvrwjblond) = vjnpkwaeom qeghvrisza (wimfedsthj )	Positive	20 Jun 2026
NCT05649137 (STEP UP T2D, ADA2026)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	512	Semaglutide 2.4 mg	xppfmyyufd(bcasuaexln) = zaemmcyedz fqubllkzex (wrjpkurlws )	Positive	20 Jun 2026
				Placebo	uwepcqispi(ilxhmufysi) = pupnlymdzf rsekxsimlu (zrtfjkawpu ) View more
SELECT (ADA2026)	Not Applicable	Cardiovascular Diseases \| Obesity	17,017	Semaglutide 2.4mg (Asian)	uemkshyimx(xvrnkoetog) = hpuumlzdpt oijvaldqzd (ztmkrlalph )	Positive	20 Jun 2026
				Semaglutide 2.4mg (Hispanic)	uemkshyimx(xvrnkoetog) = crepjioeta oijvaldqzd (ztmkrlalph )
NCT04707469 (PIONEER PLUS, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	262	Oral Semaglutide 14 mg	qlwedmzplq(hbpkkfbrhw) = tmrdlcguke ajgjbtdoyl (agazamknuf ) View more	Positive	20 Jun 2026
				Oral Semaglutide 25 mg	qlwedmzplq(hbpkkfbrhw) = besvicnhri ajgjbtdoyl (agazamknuf )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis